Study: NCT00548769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.